➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Last Updated: December 2, 2020

DrugPatentWatch Database Preview

Patent: 9,234,211

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,234,211

Title:	Hybrid promoter and recombinant vector comprising the same
Abstract:	The present invention relates to a hybrid promoter, in which a whole or a part of a CMV enhancer, a whole or a part of a .beta.-actin promoter, a whole or a part of a CMV promoter, and a whole or a part of a .beta.-actin intron are operably linked to each other, a recombinant vector comprising the same, a transformant transformed with the recombinant vector, a pharmaceutical composition comprising the recombinant vector or the transformant, and a method for preparing a target protein using the recombinant vector or the transformant. The hybrid promoter of the present invention is able to induce high expression of a target protein in a eukaryotic cell. Therefore, the hybrid promoter of the present invention can be effectively used for the development of an antibody or the production of a DNA vaccine.
Inventor(s):	Kim; Yeon Chul (Daejeon, KR), Jung; Saem (Daejeon, KR), Jung; Jun (Daejeon, KR)
Assignee:	LG Life Sciences Ltd. (Seoul, KR)
Application Number:	13/990,546
Patent Claims:	see list of patent claims

Details for Patent 9,234,211

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Schering	INTRON A	interferon alfa-2b	VIAL	103132	003	1986-06-04	Start Trial	LG Life Sciences Ltd. (Seoul, KR)	2030-11-30	RX		search
Schering	INTRON A	interferon alfa-2b	VIAL	103132	002	1986-06-04	Start Trial	LG Life Sciences Ltd. (Seoul, KR)	2030-11-30	RX		search
Schering	INTRON A	interferon alfa-2b	VIAL	103132	001	1986-06-04	Start Trial	LG Life Sciences Ltd. (Seoul, KR)	2030-11-30	RX		search
Smith And Nephew	SANTYL	collagenase	OINTMENT;TOPICAL	101995	001	1965-06-04	Start Trial	LG Life Sciences Ltd. (Seoul, KR)	2030-11-30	RX		search
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

International Patent Family for US Patent 9,234,211

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2012074277	Start Trial
United States of America	2013324593	Start Trial
South Korea	101038126	Start Trial
Japan	2014502159	Start Trial
Japan	2016104017	Start Trial
Japan	5918782	Start Trial
Hungary	E035311	Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

By using our website you are consenting to our use of cookies in accordance with our privacy policy.